Interestingly, a recently published report claims that IKKα, the other catalytic subunit of the IKK complex, would be a better actionable target in KRAS-induced lung cancer, suggesting combined IKKα and IKKβ inhibition as a therapeutic approach [58]. This evidence concerns the gene KRAS and lung cancer.